替吉奥单药对比吉西他滨单药一线治疗老年晚期胰腺癌的临床效果分析

Clinical effect of tegafur,gimeracil and oteracil porassium versus gemcitabine in the first-line treatment of elderly patients with advanced pancreatic cancer

目的分析替吉奥单药对比吉西他滨单药一线治疗老年晚期胰腺癌的临床效果。方法74例老年晚期胰腺癌患者,根据用药方案不同分为观察组和对照组,各37例。观察组采取替吉奥单药治疗,对照组采取吉西他滨单药治疗。比较两组临床疗效、不良反应发生率、生存时间。结果两组总缓解率比较差异无统计学意义(P>0.05)。观察组不良反应发生率16.2%低于对照组的40.5%,差异有统计学意义(P<0.05)。随访1年,两组生存时间比较差异无统计学意义(P>0.05)。结论替吉奥单药治疗老年晚期胰腺癌的疗效与吉西他滨单药治疗的效果相当,但安全性要明显高于吉西他滨,值得推广使用。

Objective To analyze the clinical effect of tegafur,gimeracil and oteracil porassium versus gemcitabine in the first-line treatment of elderly patients with advanced pancreatic cancer.Methods A total of 74 elderly patients with advanced pancreatic cancer were divided into observation group and control group according to different medication schemes,with 37 cases in each group.The observation group was treated with tegafur,gimeracil and oteracil porassium,and the control group was treated with gemcitabine monotherapy.The clinical efficacy,incidence of adverse reactions,and survival time were compared between the two groups.Results There was no statistically significant difference in the overall remission rate between the two groups(P>0.05).The incidence of adverse reactions 16.2% in the observation group was lower than 40.5% in the control group,and the difference was statistically significant(P<0.05).After 1 year of follow-up,there was no statistically significant difference in the survival time between the two groups(P>0.05).Conclusion The efficacy of S-1 in the treatment of elderly patients with advanced pancreatic cancer is similar to that of gemcitabine,but its safety is significantly higher than that of gemcitabine,which is worthy of promotion and application.